Abstract
The mechanism of 2′-C-cyano-2′-deoxy-1-β-d-arabino-pentofuranosylcytosine (CNDAC) action was investigated in human lymphoblastoid CEM cells and myeloblastic leukemia ML-1 cells. CNDAC was metabolized to its 5′-triphosphate and incorporated into DNA, which was associated with inhibition of DNA synthesis. After incubation of cells with [3H]CNDAC, metabolites were detected in 3′→5′ phosphodiester linkage and at the 3′ terminus of cellular DNA. Specific enzymatic hydrolysis of DNA demonstrated that the parent nucleoside and its 2′-epimer 2′-C-cyano-2′-deoxy-2-ribo-pentofuranosylcytosine accounted for approximately 65% of the total analogs incorporated into DNA and essentially all of the drug in the 3′→5′ phosphodiester linkage. In contrast, all detectable radioactivity at 3′ termini was associated with 2′-C-cyano-2′,3′-didehydro-2′,3′-dideoxycytidine. This de facto DNA chain-terminating nucleotide arises from an electronic characteristic and cleavage of the 3′-phosphodiester bond subsequent to the addition of a nucleotide to the incorporated CNDAC moiety by β-elimination, a process that generates a single strand break in DNA. Investigation of the biological consequences of these actions indicated that, after incubation with cytostatic concentrations of CNDAC, cell cycle progression was delayed during S phase, but that cells arrested predominantly in the G2 phase. This differed from the S phase-arresting actions of ara-C and gemcitabine, other deoxycytidine analogs that inhibit DNA replication but do not cause strand breaks. Thus, once incorporated into DNA, the CNDAC molecule appears to act by a dual mechanism that 1) delays the progress of further DNA replication, but 2) upon addition of a deoxynucleotide results in the conversion of the incorporated analog to a de facto DNA chain terminator at the 3′ terminus of a single strand break. It is likely that DNA strand breaks trigger cell cycle arrest in G2.
Footnotes
- Received September 15, 2000.
- Accepted December 15, 2000.
-
Send reprint requests to: William Plunkett, Ph.D., Department of Experimental Therapeutics, Box 71, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030. E-mail: wplunket{at}mdanderson.org
-
This work was funded in part by Grant CA28596 from the National Cancer Institute, Department of Health and Human Services, Bethesda, MD, and by Sankyo Company Ltd., Tokyo, Japan.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|